



# Nerlynx® (Neratinib) Prior Authorization Form

Member Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Member ID#: \_\_\_\_\_

## Drug Information

Pharmacy Billing (NDC: \_\_\_\_\_) Start Date (or date of next dose): \_\_\_\_\_

Dose: \_\_\_\_\_ Regimen: \_\_\_\_\_

## Billing Provider Information

Pharmacy NPI: \_\_\_\_\_ Pharmacy Name: \_\_\_\_\_

Pharmacy Phone: \_\_\_\_\_ Pharmacy Fax: \_\_\_\_\_

## Prescriber Information

Prescriber NPI: \_\_\_\_\_ Prescriber Name: \_\_\_\_\_

Prescriber Phone: \_\_\_\_\_ Prescriber Fax: \_\_\_\_\_ Specialty: \_\_\_\_\_

## Criteria

**For Initial Authorization (Initial approval will be for the duration of 6 months):**

1. Please indicate the diagnosis and information:

**Non-metastatic Breast Cancer**

A. Does member have early stage breast cancer? Yes \_\_\_ No \_\_\_

B. Does member have Human Epidermal Receptor Type 2 (HER2)-overexpressed (positive) breast cancer? Yes \_\_\_ No \_\_\_

C. Is neratinib to follow adjuvant trastuzumab-based therapy? Yes \_\_\_ No \_\_\_

**Recurrent or Metastatic Breast Cancer**

A. Does member have recurrent or metastatic breast cancer? Yes \_\_\_ No \_\_\_

B. Does member have HER2-positive breast cancer? Yes \_\_\_ No \_\_\_

C. Will neratinib be used in combination with capecitabine? Yes \_\_\_ No \_\_\_

D. If member has brain metastases, will neratinib be used in combination with capecitabine or paclitaxel? Yes \_\_\_ No \_\_\_

**If answer is none of the above, please indicate diagnosis:** \_\_\_\_\_

Additional Information: \_\_\_\_\_

**For Continued Authorization:**

1. Date of last dose: \_\_\_\_\_

2. Does member have any evidence of progressive disease while on neratinib? Yes \_\_\_ No \_\_\_

3. Has the member experienced adverse drug reactions related to neratinib therapy? Yes \_\_\_ No \_\_\_

If yes, please specify adverse reactions: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.**

*Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.*

### CONFIDENTIALITY NOTICE

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at [AetnaBetterHealth.com/Oklahoma](http://AetnaBetterHealth.com/Oklahoma).

*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*